The cost of returning to normal activities may not only be a spike in COVID and the more common coronavirus the “common” cold, but influenza. Testing for both coronaviruses and influenza should be standard operating procedure at the first sign of symptoms.
Current research makes accurate determination of HCV genotype critical for the development of novel therapies for hepatitis C.
Current reimbursement and regulatory roadblocks inhibit the rapid development and deployment of potentially life-saving molecular diagnostics, according to this paper.
